Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.
about
Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.
P2860
Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Development and Evaluation of ...... Lipid A, as a Cancer Vaccine.
@ast
Development and Evaluation of ...... Lipid A, as a Cancer Vaccine.
@en
type
label
Development and Evaluation of ...... Lipid A, as a Cancer Vaccine.
@ast
Development and Evaluation of ...... Lipid A, as a Cancer Vaccine.
@en
prefLabel
Development and Evaluation of ...... Lipid A, as a Cancer Vaccine.
@ast
Development and Evaluation of ...... Lipid A, as a Cancer Vaccine.
@en
P2860
P1476
Development and Evaluation of ...... l Lipid A, as a Cancer Vaccine
@en
P2093
Kawther K Ahmed
Sean M Geary
P2860
P304
P356
10.1016/J.XPHS.2015.11.042
P407
P577
2016-01-30T00:00:00Z